When Demand for Peptides Outruns Regulation, Gray Markets Fill the Gap

‍Guest Author: Kurt Lunkwitz, founder and president of BoomRx

On Oct. 6, 2023, the U.S. Food and Drug Administration (FDA) updated its bulk drug substances list for compounding, placing a number of peptides into Category 2 and effectively removing them from legitimate compounding channels.

The peptide reclassification announcement was not a policy win. 

What happened? Demand for peptides did not disappear. It migrated—and compliance suffered.

For nearly three years, 19 peptides sat on the FDA's Category 2 list. Effectively banned from compounding. No legitimate safety signal required it. But the policy stood.

Patients migrated to unregulated sources. No Certificates of Analysis. No Current Good Manufacturing Practice (cGMP) standards. No chain of custody. No prescriber oversight. Products were being manufactured in facilities that have never seen an FDA inspector, sourced from supply chains that have never been audited. Peptide medications were marketed like candy-store selections, displayed on the digital storefronts of dozens of online retailers boldly labeled “not for human use.”

This should never have happened. But it did.

Meanwhile, clinical and commercial interest in peptides has continued to grow. The U.S. peptide therapeutics market had an estimated valuation of $21 billion in 2025 and is projected to grow to nearly $35 billion by 2035.

What seemed like a healthcare story was really a supply-chain problem.

Every operations executive understands this principle: when you eliminate the regulated channel without eliminating the demand, you effectively reduce compliance. A parallel supply chain then develops with zero quality control.

The Gray Market Was the Warning Label

The FDA has since announced plans to move a number of those peptides back to Category 1. Back into the regulated sourcing infrastructure. Back into 503A and 503B compounding facilities where API manufacturers are fully vetted, APIs are third-party tested, manufacturing meets cGMP standards, and a physician writes the prescription.

Here is what we should take from this:

The gray market was never the competition. It was the warning label.

It told us exactly what happens when policy prioritizes restriction over infrastructure, when the instinct is to shut down access instead of building a better supply chain around it.

Policy can restrict access. But it cannot restrict demand. And any system that confuses one for the other will always produce the same result.

Regulated Infrastructure Is the Real Safety Net

At BoomRx, we work with vetted 503B and 503A compounding facilities that have heavily invested in the infrastructure necessary to deliver quality and compliant medications. That means: Manufacturing capacity. Quality systems. API sourcing and verification. 

Their operational thesis never changed. There was no world in which the starting base materials and APIs weren't sourced from FDA-registered, FDA-inspected, cGMP manufacturers, the same manufacturers later added to the FDA’s “Green List.”

Infrastructure doesn’t stop at manufacturing. It also includes the systems healthcare providers use to access regulated supply chains without navigating fragmented vendors, inconsistent fulfillment processes, or unclear sourcing pathways.

As personalized medicine programs expand across telehealth practices, wellness clinics, and physician-led specialty care, healthcare providers increasingly need operational systems that simplify how therapies move from regulated manufacturing environments to the clinical setting.

Technology platforms that consolidate pharmacy access, sourcing, and fulfillment into a single operational layer can help restore clarity to the system while keeping therapies inside regulated supply chains.

The safest patient is the one inside a regulated supply chain. Full stop.

The Question Healthcare Should Be Asking

The real concern moves beyond what just happened with peptides.

In healthcare, we all should be asking ourselves: What else are we restricting today that is quietly building the next gray market for tomorrow?

When demand outpaces the systems designed to safely deliver care, the market always responds.

The only real question is whether that response happens inside a regulated supply chain or outside of it.